智通财经APP获悉,云顶新耀(01952)尾盘涨超5%,截至发稿,涨4.86%,报73.35港元,成交额4.99亿港元。
消息面上,8月15日,云顶新耀宣布,其核心产品艾曲莫德被纳入《2025 ACG临床指南:成人溃疡性结肠炎》,新版指南强烈推荐艾曲莫德用于中重度活动性溃疡性结肠炎(UC)患者的诱导缓解治疗及维持缓解治疗。此前,艾曲莫德已被纳入2024年美国胃肠病学协会(AGA)临床实践指南,推荐作为溃疡性结肠炎的一线治疗。连续获得两大国际权威指南背书,不仅印证了其临床价值,也凸显其填补溃疡性结肠炎治疗空白的潜力。
值得注意的是,云顶新耀近日宣布,将向天境生物注资3090万美元,交易完成后,其持股比例为16.1%,跃升为后者第一大股东。交银国际认为,通过此次战略投资,公司有机会利用天境差异化的4-1BB平台、双抗管线及海外临床转化能力,与其现有的mRNA肿瘤疫苗布局形成协同。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.